SiRNA Delivery to the lung: What's new?

Advanced Drug Delivery Reviews

Volumn 75, Issue , 2014, Pages 112-128

  Merkel, Olivia M ^a,b   Rubinstein, Israel ^c,e   Kissel, Thomas ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Asthma; Lung cancer; Nanocarrier; Polymer; Pulmonary delivery; SiRNA

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; POLYMERS;

ASTHMA; LUNG CANCER; NANOCARRIERS; PULMONARY DELIVERY; SIRNA;

RNA;

ANTISENSE OLIGONUCLEOTIDE; ATELOCOLLAGEN; BOVINE SERUM ALBUMIN; CHITOSAN; CISPLATIN; GOLD NANOPARTICLE; INTERLEUKIN 10; INTERLEUKIN 6; LIPID CALCIUM PHOSPHATE NANOPARTICLE; LIPOPLEX; LOCKED NUCLEIC ACID; MESOPOROUS SILICA NANOPARTICLE; MONOCYTE CHEMOTACTIC PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NANOCARRIER; NANOPARTICLE; PEPTIDE; PHOSPHOROTHIOIC ACID; POLYETHYLENEIMINE; POLYGLACTIN; POLY[2 (DIMETHYLAMINO)ETHYL METHACRYLATE]; R3V6 PEPTIDE; SMALL INTERFERING RNA; SPERMINE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG CARRIER;

ACUTE LUNG INJURY; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASTHMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DRUG EFFICACY; DRUG FORMULATION; DRUG SENSITIVITY; GENE DELIVERY SYSTEM; GENE SILENCING; HUMAN; KIDNEY CLEARANCE; LUNG; LUNG CANCER; LUNG CLEARANCE; LUNG FIBROSIS; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; RNA METHYLATION; RNA SEQUENCE; SYSTEMIC CIRCULATION; THERAPY EFFECT; TRANSCYTOSIS; TUMOR VOLUME; ANIMAL; CHEMISTRY; DISEASE MODEL; INHALATIONAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; LUNG; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84908224696     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.018     Document Type: Review

References (163)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Agrawal N., Dasaradhi P.V., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 2003, 67:657-685.
3. Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 2005, 23:222-226.
4. Hammond S.M., Boettcher S., Caudy A.A., Kobayashi R., Hannon G.J. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001, 293:1146-1150.
5. Ryszard K., Adrian R.K., Sidney A. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11:125-140.
6. Detzer A., Overhoff M., Mescalchin A., Rompf M., Sczakiel G. Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Curr. Pharm. Des. 2008, 14:3666-3673.
7. Thomas M., Lu J.J., Chen J., Klibanov A.M. Non-viral siRNA delivery to the lung. Adv. Drug Deliv. Rev. 2007, 59:124-133.
8. de Fougerolles A., Novobrantseva T. siRNA and the lung: research tool or therapeutic drug?. Curr. Opin. Pharmacol. 2008, 8:280-285.
9. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6:686-695.
10. Zheng M., Librizzi D., Kilic A., Liu Y., Renz H., Merkel O.M., Kissel T. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials 2012, 33:6551-6558.
11. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006, 13:541-552.
12. Merkel O.M., Librizzi D., Pfestroff A., Schurrat T., Buyens K., Sanders N.N., De Smedt S.C., Behe M., Kissel T. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J. Control. Release 2009, 138:148-159.
13. Burke R.S., Pun S.H. Extracellular barriers to in vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjug. Chem. 2008, 19:693-704.
14. Cryan S.A., Sivadas N., Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv. Drug Deliv. Rev. 2007, 59:1133-1151.
15. Durcan N., Murphy C., Cryan S.A. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol. Pharm. 2008, 5:559-566.
16. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac. Soc. 2004, 1:315-320.
17. Carvalho T.C., Peters J.I., Williams R.O. Influence of particle size on regional lung deposition-what evidence is there?. Int. J. Pharm. 2011, 406:1-10.
18. Madl P., Hussain M., Khan A. Lung deposition predicoins of airborne particles and the emergence of contemporary diseases Part-I. Health 2011, 2:51-59.
19. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
20. Bauer K.H., Frömming K.H., Führer C. Pharmazeutische Technologie 1989, Thieme.
21. Daigle C.C., Chalupa D.C., Gibb F.R., Morrow P.E., Oberdorster G., Utell M.J., Frampton M.W. Ultrafine particle deposition in humans during rest and exercise. Inhal. Toxicol. 2003, 15:539-552.
22. Pietropaoli A.P., Frampton M.W., Hyde R.W., Morrow P.E., Oberdorster G., Cox C., Speers D.M., Frasier L.M., Chalupa D.C., Huang L.S., Utell M.J. Pulmonary function, diffusing capacity, and inflammation in healthy and asthmatic subjects exposed to ultrafine particles. Inhal. Toxicol. 2004, 16(Suppl. 1):59-72.
23. Frampton M.W., Utell M.J., Zareba W., Oberdorster G., Cox C., Huang L.S., Morrow P.E., Lee F.E., Chalupa D., Frasier L.M., Speers D.M., Stewart J. Effects of exposure to ultrafine carbon particles in healthy subjects and subjects with asthma. Res. Rep. Health Eff. Inst. 2004, 1-47. (discussion 49-63).
24. Merkel O.M., Kissel T. Nonviral pulmonary delivery of siRNA. Acc. Chem. Res. 2012, 45:961-970.
25. Merkel O.M., Zheng M., Debus H., Kissel T.H. Pulmonary gene delivery using polymeric non-viral vectors. Bioconjug. Chem. 2012, 23(1):3-20.
26. Lam J.K.-W., Liang W., Chan H.-K. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 2012, 64(1):1-15.
27. Fujita Y., Takeshita F., Kuwano K., Ochiya T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals (Basel) 2013, 6:223-250.
28. Braasch D.A., Paroo Z., Constantinescu A., Ren G., Oz O.K., Mason R.P., Corey D.R. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 2004, 14:1139-1143.
29. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36:2136-2151.
30. Bramsen J.B., Laursen M.B., Nielsen A.F., Hansen T.B., Bus C., Langkjaer N., Babu B.R., Hojland T., Abramov M., Van Aerschot A., Odadzic D., Smicius R., Haas J., Andree C., Barman J., Wenska M., Srivastava P., Zhou C., Honcharenko D., Hess S., Muller E., Bobkov G.V., Mikhailov S.N., Fava E., Meyer T.F., Chattopadhyaya J., Zerial M., Engels J.W., Herdewijn P., Wengel J., Kjems J. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009, 37:2867-2881.
31. Moschos S.A., Frick M., Taylor B., Turnpenny P., Graves H., Spink K.G., Brady K., Lamb D., Collins D., Rockel T.D., Weber M., Lazari O., Perez-Tosar L., Fancy S.A., Lapthorn C., Green M.X., Evans S., Selby M., Jones G., Jones L., Kearney S., Mechiche H., Gikunju D., Subramanian R., Uhlmann E., Jurk M., Vollmer J., Ciaramella G., Yeadon M. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol. Ther. 2011, 19:2163-2168.
32. Simpson A.A., Tao Y., Leiman P.G., Badasso M.O., He Y., Jardine P.J., Olson N.H., Morais M.C., Grimes S., Anderson D.L., Baker T.S., Rossmann M.G. Structure of the bacteriophage [phis]29 DNA packaging motor. Nature 2000, 408:745-750.
33. Qiu C., Peng W.K., Shi F., Zhang T. Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene. Genet. Mol. Res. 2012, 11:3236-3245.
34. Hamasaki T., Suzuki H., Shirohzu H., Matsumoto T., D'Alessandro-Gabazza C.N., Gil-Bernabe P., Boveda-Ruiz D., Naito M., Kobayashi T., Toda M., Mizutani T., Taguchi O., Morser J., Eguchi Y., Kuroda M., Ochiya T., Hayashi H., Gabazza E.C., Ohgi T. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One 2012, 7:e42655.
35. Fujita Y., Takeshita F., Mizutani T., Ohgi T., Kuwano K., Ochiya T. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci. Rep. 2013, 3:3325.
36. De Backer L., Braeckmans K., Demeester J., De Smedt S.C., Raemdonck K. The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels. Nanomedicine (Lond.) 2013, 8:1625-1638.
37. Lomas-Neira J., Perl M., Venet F., Chung C.S., Ayala A. The role and source of tumor necrosis factor-alpha in hemorrhage-induced priming for septic lung injury. Shock 2012, 37:611-620.
38. Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., MacLachlan I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 2008, 19:991-999.
39. D'Alessandro-Gabazza C.N., Kobayashi T., Boveda-Ruiz D., Takagi T., Toda M., Gil-Bernabe P., Miyake Y., Yasukawa A., Matsuda Y., Suzuki N., Saito H., Yano Y., Fukuda A., Hasegawa T., Toyobuku H., Rennard S.I., Wagner P.D., Morser J., Takei Y., Taguchi O., Gabazza E.C. Development and preclinical efficacy of novel transforming growth factor-beta1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 46:397-406.
40. Hama S., Arata M., Nakamura I., Kasetani T., Itakura S., Tsuchiya H., Yoshiki T., Kogure K. Prevention of tumor growth by needle-free jet injection of anti-C7orf24 siRNA. Cancer Gene Ther. 2012, 19:553-557.
41. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4:346-358.
42. Wu F., Liu Y., Lv X., Miao X., Sun Y., Yu W. Small interference RNA targeting TLR4 gene effectively attenuates pulmonary inflammation in a rat model. J. Biomed. Biotechnol. 2012, 2012:406435.
43. Xia L., Guan W., Wang D., Zhang Y.S., Zeng L.L., Li Z.P., Wang G., Yang Z.Z. Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer. Biomed. Res. Int. 2013, 2013:957913.
44. Gu X., Cun Y., Li M., Qing Y., Jin F., Zhong Z., Dai N., Qian C., Sui J., Wang D. Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells. Int. J. Med. Sci. 2013, 10:870-882.
45. Wang X.M., Cui J.W., Li W., Cai L., Song W., Wang G.J. Silencing of the COPS3 gene by siRNA reduces proliferation of lung cancer cells most likely via induction of cell cycle arrest and apoptosis. Asian Pac. J. Cancer Prev. 2012, 13:1043-1048.
46. Lian Y.X., Chen R., Xu Y.H., Peng C.L., Hu H.C. Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer. Gene 2012, 511:169-176.
47. Liu Y., Yan X., Liu N., Zhou J., Liu J., Pang H., Cao J., Wang Y., Liu L., Zhang H. Lentivirus-delivered ZEB-1 small interfering RNA inhibits lung adenocarcinoma cell growth in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2012, 138:1329-1338.
48. Caino M.C., Lopez-Haber C., Kim J., Mochly-Rosen D., Kazanietz M.G. Proteins kinase Cvarepsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene 2012, 31:2593-2600.
49. Dehousse V., Garbacki N., Colige A., Evrard B. Development of pH-responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery. Biomaterials 2010, 31:1839-1849.
50. Fernandez C.A., Rice K.G. Engineered nanoscaled polyplex gene delivery systems. Mol. Pharm. 2009, 6:1277-1289.
51. Patil J.S., Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India 2012, 29:44-49.
52. Yadava P., Gibbs M., Castro C., Hughes J.A. Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS PharmSciTech 2008, 9:335-341.
53. Kasper J.C., Schaffert D., Ogris M., Wagner E., Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability-a step closer from promising technology to application. J. Control. Release 2011, 151(3):246-255.
54. Matsubara H., Sakakibara K., Kunimitsu T., Matsuoka H., Kato K., Oyachi N., Dobashi Y., Matsumoto M. Non-small cell lung carcinoma therapy using mTOR-siRNA. Int. J. Clin. Exp. Pathol. 2012, 5:119-125.
55. Chen G., Kronenberger P., Teugels E., Umelo I.A., De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012, 10:28.
56. Zhang Y.P., Li W.B., Wang W.L., Liu J., Song S.X., Bai L.L., Hu Y.Y., Yuan Y.D., Zhang M. siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Acta Pharmacol. Sin. 2012, 33:897-908.
57. Huang B., Zhou H., Wang X., Liu Z. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013, 13:8.
58. Liu Y., Dong Q.Z., Wang S., Fang C.Q., Miao Y., Wang L., Li M.Z., Wang E.H. Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer. BMC Cancer 2013, 13:346.
59. Rahman M.A., Amin A.R., Wang D., Koenig L., Nannapaneni S., Chen Z., Wang Z., Sica G., Deng X., Chen Z.G., Shin D.M. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin. Cancer Res. 2013, 19:3416-3428.
60. Cao W., Ribeiro Rde O., Liu D., Saintigny P., Xia R., Xue Y., Lin R., Mao L., Ren H. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One 2013, 7:e52984.
61. Nishimura Y., Takiguchi S., Ito S., Itoh K. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line. Int. J. Oncol. 2014, 44:412-426.
62. Wang Y., Chen L., Huang G., He D., He J., Xu W., Zou C., Zong F., Li Y., Chen B., Wu S., Zhao W., Wu J. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One 2013, 8:e57391.
63. Ramachandran S., Krishnamurthy S., Jacobi A.M., Wohlford-Lenane C., Behlke M.A., Davidson B.L., McCray P.B. Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 305:L23-L32.
64. Fourtounis J., Wang I.M., Mathieu M.C., Claveau D., Loo T., Jackson A.L., Peters M.A., Therien A.G., Boie Y., Crackower M.A. Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene. Respir. Res. 2012, 13:92.
65. Khatri N., Misra A. Development of siRNA lipoplexes for intracellular delivery in lung cancer cells. J. Pharm. Bioallied Sci. 2012, 4:S1-S3.
66. Biswas S., Knipp R.J., Gordon L.E., Nandula S.R., Gorr S.U., Clark G.J., Nantz M.H. Hydrophobic oxime ethers: a versatile class of pDNA and siRNA transfection lipids. ChemMedChem 2011, 6:2063-2069.
67. Shim G., Choi H.W., Lee S., Choi J., Yu Y.H., Park D.E., Choi Y., Kim C.W., Oh Y.K. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol. Ther. 2013, 21:816-824.
68. Fehring V., Schaeper U., Ahrens K., Santel A., Keil O., Eisermann M., Giese K., Kaufmann J. Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC. Mol. Ther. 2014, 22(4):811-820.
69. Polach K.J., Matar M., Rice J., Slobodkin G., Sparks J., Congo R., Rea-Ramsey A., McClure D., Brunhoeber E., Krampert M., Schuster A., Jahn-Hofmann K., John M., Vornlocher H.P., Fewell J.G., Anwer K., Geick A. Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol. Ther. 2012, 20:91-100.
70. Schlegel A., Largeau C., Bigey P., Bessodes M., Lebozec K., Scherman D., Escriou V. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J. Control. Release 2011, 152:393-401.
71. Bardita C., Predescu D., Justice M.J., Petrache I., Predescu S. In vivo knockdown of intersectin-1s alters endothelial cell phenotype and causes microvascular remodeling in the mouse lungs. Apoptosis 2013, 18:57-76.
72. Bardita C., Predescu D., Predescu S. Long-term silencing of intersectin-1s in mouse lungs by repeated delivery of a specific siRNA via cationic liposomes. Evaluation of knockdown effects by electron microscopy. J. Vis. Exp. 2013, 10.3791/50316.
73. McCaskill J., Singhania R., Burgess M., Allavena R., Wu S., Blumenthal A., McMillan N.A. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol. Ther. Nucleic Acids 2013, 2:e96.
74. Shi B., Keough E., Matter A., Leander K., Young S., Carlini E., Sachs A.B., Tao W., Abrams M., Howell B., Sepp-Lorenzino L. Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J. Histochem. Cytochem. 2011, 59:727-740.
75. Wang C., Ding C., Kong M., Dong A., Qian J., Jiang D., Shen Z. Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2012, 410:537-542.
76. Tian H., Liu S., Zhang J., Zhang S., Cheng L., Li C., Zhang X., Dail L., Fan P., Dai L., Yan N., Wang R., Wei Y., Deng H. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. J. Biomed. Nanotechnol. 2012, 8:633-641.
77. Gaspar M.M., Bakowsky U., Ehrhardt C. Inhaled liposomes-current strategies and future challenges. J. Biomed. Nanotechnol. 2008, 4:245-257.
78. Lam J.K.-W., Liang W., Chan H.-K. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 2012, 64:1-15.
79. Clark K.L., Hughes S.A., Bulsara P., Coates J., Moores K., Parry J., Carr M., Mayer R.J., Wilson P., Gruenloh C., Levin D., Darton J., Weber W.M., Sobczak K., Gill D.R., Hyde S.C., Davies L.A., Pringle I.A., Sumner-Jones S.G., Jadhav V., Jamison S., Strapps W.R., Pickering V., Edbrooke M.R. Pharmacological characterization of a novel ENaCalpha siRNA (GSK2225745) with potential for the treatment of cystic fibrosis. Mol. Ther. Nucleic Acids 2013, 2:e65.
80. Mainelis G., Seshadri S., Garbuzenko O.B., Han T., Wang Z., Minko T. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:345-354.
81. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 2002, 54:715-758.
82. Han S., Mahato R.I., Sung Y.K., Kim S.W. Development of biomaterials for gene therapy. Mol. Ther. 2000, 2:302-317.
83. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4:581-593.
84. Beyerle A., Long A.S., White P.A., Kissel T., Stoeger T. Poly(ethylene imine) nanocarriers do not induce mutations nor oxidative DNA damage in vitro in MutaMouse FE1 cells. Mol. Pharm. 2011, 8:976-981.
85. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 2010, 62(1):12-27.
86. Okuda T., Kito D., Oiwa A., Fukushima M., Hira D., Okamoto H. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol. Pharm. Bull. 2013, 36:1183-1191.
87. Luo Y., Zhai X., Ma C., Sun P., Fu Z., Liu W., Xu J. An inhalable beta(2)-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J. Control. Release 2012, 162:28-36.
88. Park S.C., Nam J.P., Kim Y.M., Kim J.H., Nah J.W., Jang M.K. Branched polyethylenimine-grafted-carboxymethyl chitosan copolymer enhances the delivery of pDNA or siRNA in vitro and in vivo. Int. J. Nanomedicine 2013, 8:3663-3677.
89. Liu S., Nugroho A.E., Shudou M., Maeyama K. Regulation of mucosal mast cell activation by short interfering RNAs targeting syntaxin4. Immunol. Cell Biol. 2012, 90:337-345.
90. Han J., Wang Q., Zhang Z., Gong T., Sun X. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 2014, 10(3):524-535.
91. Merkel O.M., Zheng M., Mintzer M.A., Pavan G.M., Librizzi D., Maly M., Hoffken H., Danani A., Simanek E.E., Kissel T. Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J. Control. Release 2011, 153:23-33.
92. Merkel O.M., Beyerle A., Librizzi D., Pfestroff A., Behr T.M., Sproat B., Barth P.J., Kissel T. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 2009, 6:1246-1260.
93. Rosenecker J., Naundorf S., Gersting S.W., Hauck R.W., Gessner A., Nicklaus P., Muller R.H., Rudolph C. Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J. Gene Med. 2003, 5:49-60.
94. Eliyahu H., Siani S., Azzam T., Domb A.J., Barenholz Y. Relationships between chemical composition, physical properties and transfection efficiency of polysaccharide-spermine conjugates. Biomaterials 2006, 27:1646-1655.
95. Jiang H.L., Lim H.T., Kim Y.K., Arote R., Shin J.Y., Kwon J.T., Kim J.E., Kim J.H., Kim D., Chae C., Nah J.W., Choi Y.J., Cho C.S., Cho M.H. Chitosan-graft-spermine as a gene carrier in vitro and in vivo. Eur. J. Pharm. Biopharm. 2011, 77:36-42.
96. Allen J.C. Biochemistry of the polyamines. Cell Biochem. Funct. 1983, 1:131-140.
97. Tabor C.W., Tabor H. Polyamines. Annu. Rev. Biochem. 1984, 53:749-790.
98. Igarashi K., Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem. Biophys. Res. Commun. 2000, 271:559-564.
99. Pavan G.M., Mintzer M.A., Simanek E.E., Merkel O.M., Kissel T., Danani A. Computational insights into the interactions between DNA and siRNA with "rigid" and "flexible" triazine dendrimers. Biomacromolecules 2010, 11:721-730.
100. Elsayed M., Corrand V., Kolhatkar V., Xie Y., Kim N.H., Kolhatkar R., Merkel O.M. Influence of oligospermines architecture on their suitability for siRNA delivery. Biomacromolecules 2014, 15:1299-1310.
101. Jiang H.L., Hong S.H., Kim Y.K., Islam M.A., Kim H.J., Choi Y.J., Nah J.W., Lee K.H., Han K.W., Chae C., Cho C.S., Cho M.H. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int. J. Pharm. 2011, 420:256-265.
102. Hong S.H., Kim J.E., Kim Y.K., Minai-Tehrani A., Shin J.Y., Kang B., Kim H.J., Cho C.S., Chae C., Jiang H.L., Cho M.H. Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1. Int. J. Nanomedicine 2012, 7:2293-2306.
103. Hong S.H., Minai-Tehrani A., Chang S.H., Jiang H.L., Lee S., Lee A.Y., Seo H.W., Chae C., Beck G.R., Cho M.H. Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS One 2013, 8:e77121.
104. Kang J.-H., Tachibana Y., Kamata W., Mahara A., Harada-Shiba M., Yamaoka T. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier. Bioorg. Med. Chem. 2010, 18:3946-3950.
105. Boyer C., Teo J., Phillips P., Erlich R.B., Sagnella S., Sharbeen G., Dwarte T., Duong H.T.T., Goldstein D., Davis T.P., Kavallaris M., McCarroll J. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol. Pharm. 2013, 10:2435-2444.
106. Yu H., Xu Z., Chen X., Xu L., Yin Q., Zhang Z., Li Y. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Macromol. Biosci. 2014, 14(1):100-109.
107. Yu H., Zou Y., Jiang L., Yin Q., He X., Chen L., Zhang Z., Gu W., Li Y. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013, 34:2738-2747.
108. Srinivasan S., Selvan S.T., Archunan G., Gulyas B., Padmanabhan P. MicroRNAs-the next generation therapeutic targets in human diseases. Theranostics 2013, 3:930-942.
109. Kedinger V., Meulle A., Zounib O., Bonnet M.E., Gossart J.B., Benoit E., Messmer M., Shankaranarayanan P., Behr J.P., Erbacher P., Bolcato-Bellemin A.L. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer 2013, 13:338.
110. Bonnet M.E., Gossart J.B., Benoit E., Messmer M., Zounib O., Moreau V., Behr J.P., Lenne-Samuel N., Kedinger V., Meulle A., Erbacher P., Bolcato-Bellemin A.L. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J. Control. Release 2013, 170:183-190.
111. Choi M., Lee M., Rhim T. Dexamethasone-conjugated polyethylenimine/MIF siRNA complex regulation of particulate matter-induced airway inflammation. Biomaterials 2013, 34:7453-7461.
112. Hibbitts A., Lieggi N., McCabe O., Thomas W., Barlow J., O'Brien F., Cryan S.A. Screening of siRNA nanoparticles for delivery to airway epithelial cells using high-content analysis. Ther. Deliv. 2012, 2:987-999.
113. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
114. Shen J., Yin Q., Chen L., Zhang Z., Li Y. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012, 33:8613-8624.
115. Das J., Das S., Paul A., Samadder A., Bhattacharyya S.S., Khuda-Bukhsh A.R. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicol. Lett. 2014, 225(3):454-466.
116. Su W.P., Cheng F.Y., Shieh D.B., Yeh C.S., Su W.C. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int. J. Nanomedicine 2012, 7:4269-4283.
117. Steele T.W., Zhao X., Tarcha P., Kissel T. Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery. Eur. J. Pharm. Biopharm. 2012, 80:14-24.
118. Mi Bae Y., Choi H., Lee S., Ho Kang S., Tae Kim Y., Nam K., Sang Park J., Lee M., Sig Choi J. Dexamethasone-conjugated low molecular weight polyethylenimine as a nucleus-targeting lipopolymer gene carrier. Bioconjug. Chem. 2007, 18:2029-2036.
119. Choi J.S., Ko K.S., Park J.S., Kim Y.H., Kim S.W., Lee M. Dexamethasone conjugated poly(amidoamine) dendrimer as a gene carrier for efficient nuclear translocation. Int. J. Pharm. 2006, 320:171-178.
120. Ganesh S., Iyer A.K., Weiler J., Morrissey D.V., Amiji M.M. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol. Ther. Nucleic Acids 2013, 2:e110.
121. D'Emanuele A., Attwood D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 2005, 57:2147-2162.
122. Jensen D.K., Jensen L.B., Koocheki S., Bengtson L., Cun D., Nielsen H.M., Foged C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control. Release 2012, 157:141-148.
123. Benfer M., Kissel T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur. J. Pharm. Biopharm. 2012, 80:247-256.
124. Oh B., Lee M. Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury. J. Control. Release 2014, 175:25-35.
125. Baoum A., Ovcharenko D., Berkland C. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. Int. J. Pharm. 2012, 427:134-142.
126. Li S.D., Chen Y.C., Hackett M.J., Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 2008, 16:163-169.
127. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 2012, 158:108-114.
128. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
129. Yang Y., Hu Y., Wang Y., Li J., Liu F., Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner. Mol. Pharm. 2012, 9(8):2280-2289.
130. Yang Y., Li J., Liu F., Huang L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 2012, 20:609-615.
131. Zhang Y., Schwerbrock N.M., Rogers A.B., Kim W.Y., Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 2013, 21:1559-1569.
132. Zhang Y., Peng L., Mumper R.J., Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013, 34:8459-8468.
133. Huschka R., Barhoumi A., Liu Q., Roth J.A., Ji L., Halas N.J. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano 2012, 6:7681-7691.
134. Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.P., Ibarra M.R., Baptista P.V., Stoeger T., de la Fuente J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34:7744-7753.
135. Lin D., Cheng Q., Jiang Q., Huang Y., Yang Z., Han S., Zhao Y., Guo S., Liang Z., Dong A. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo. Nanoscale 2013, 5:4291-4301.
136. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10737-10742.
137. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 2011, 19:900-914.
138. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171:349-357.
139. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 2010, 267:89-105.
140. Zamora-Avila D.E., Zapata-Benavides P., Franco-Molina M.A., Saavedra-Alonso S., Trejo-Avila L.M., Resendez-Perez D., Mendez-Vazquez J.L., Isaias-Badillo J., Rodriguez-Padilla C. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 2009, 16:892-899.
141. Nielsen E.J., Nielsen J.M., Becker D., Karlas A., Prakash H., Glud S.Z., Merrison J., Besenbacher F., Meyer T.F., Kjems J., Howard K.A. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm. Res. 2010, 27:2520-2527.
142. Lv X., Tan J., Liu D., Wu P., Cui X. Intratracheal administration of p38alpha short-hairpin RNA plasmid ameliorates lung ischemia-reperfusion injury in rats. J. Heart Lung Transplant. 2012, 31:655-662.
143. Thakkar R.K., Chung C.S., Chen Y., Monaghan S.F., Lomas-Neira J., Heffernan D.S., Cioffi W.G., Ayala A. Local tissue expression of the cell death ligand, fas ligand, plays a central role in the development of extrapulmonary acute lung injury. Shock 2011, 36:138-143.
144. Kublik H., Vidgren M.T. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 1998, 29:157-177.
145. McLean J.A., Bacon J.R., Mathews K.P., Thrall J.H., Banas J.M., Hedden J., Bayne N.K. Distribution and clearance of radioactive aerosol on the nasal mucosa. Rhinology 1984, 22:65-75.
146. Barik S. Intranasal delivery of antiviral siRNA. Methods Mol. Biol. 2011, 721:333-338.
147. Kusumoto K., Akita H., Ishitsuka T., Matsumoto Y., Nomoto T., Furukawa R., El-Sayed A., Hatakeyama H., Kajimoto K., Yamada Y., Kataoka K., Harashima H. Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano 2013, 7(9):7534-7541.
148. Iversen F., Yang C., Dagnaes-Hansen F., Schaffert D.H., Kjems J., Gao S. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 2013, 3:201-209.
149. Malek A., Merkel O., Fink L., Czubayko F., Kissel T., Aigner A. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 2009, 236:97-108.
150. W.H.Organization The top 10 causes of death. F.s. No 310 (Ed.), New York City 2008.
151. Kogure M., Takawa M., Cho H.S., Toyokawa G., Hayashi K., Tsunoda T., Kobayashi T., Daigo Y., Sugiyama M., Atomi Y., Nakamura Y., Hamamoto R. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. Cancer Lett. 2013, 336:76-84.
152. Fisher J., Zhang Y., Engelhardt J. Comparative biology of cystic fibrosis animal models. Cystic Fibrosis 2011, 311-334. Humana Press. M.D. Amaral, K. Kunzelmann (Eds.).
153. Turowska A., Librizzi D., Baumgartl N., Kuhlmann J., Dicke T., Merkel O., Homburg U., Hoffken H., Renz H., Garn H. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol. Appl. Pharmacol. 2013, 272:365-372.
154. Nials A.T., Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis. Model. Mech. 2008, 1:213-220.
155. Christopher W., Jamie S., Masayuki S., William W. Transfection of primary mouse T cells for stimulation-dependent cytokine enhancer assays. Protoc. Exch. 2007, 10.1038/nprot.2007.236.
156. Kim N., Batton D., Thakur A., Lum L., Bassett D., Merkel O. Targeted siRNA delivery to activated T cells for anti-inflammatory therapy of asthma. J. Aerosol Med. Pulm. Drug Deliv. 2013, A46-A47. (MARY ANN LIEBERT INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA).
157. Kim N.H., Nadithe V., Elsayed M., Merkel O.M. Tracking and treating activated T cells. J. Drug Deliv. Sci. Technol. 2013, 23:17-21.
158. Verdine G.L., Walensky L.D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 2007, 13:7264-7270.
159. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
160. DeVincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A., Vaishnaw A.K., Meyers R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008, 77:225-231.
161. DeVincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J., Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U. S. A. 2009, 107:8800-8805.
162. Ulanova M., Duta F., Puttagunta L., Schreiber A.D., Befus A.D. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin. Ther. Targets 2005, 9:901-921.
163. Niitsu Y., Takimoto R., Minomi K., Miyazaki M., Kajiwara K., Tanaka Y. Therapeutic Agent for Pulmonary Fibrosis 2013, (Google Patents).